{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:44:01Z","timestamp":1782506641523,"version":"3.54.5"},"reference-count":33,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Multiple myeloma, a plasma cell neoplasm is the second most common hematological malignancy in the United States. Despite significant advances in treatment armamentarium over the last decade, multiple myeloma remains an incurable malignancy. B-cell maturation antigen (BCMA) is an antigen expressed on the surface on plasma cells that can be targeted by novel mechanisms of action including antibody-drug conjugates (ADCs), bispecific T-cell engagers, and chimeric antigen receptor (CAR) T-cell therapy. This review summarizes the clinical application and development of approved and investigational immunotherapies targeting BCMA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>A search of the PubMed database was conducted using the following search terms: BCMA, CAR T, myeloma, belantamab mafodotin, and bispecific. Ongoing clinical trials, as well as abstracts from ASH and ASCO evaluating the efficacy and safety of novel agents targeting BCMA were evaluated. Prescribing information was also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Summary<\/jats:title>\n                    <jats:p>Since the discovery of BCMA as a target for myeloma, researchers have developed antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies as novel treatment modalities for myeloma patients. Belantamab mafodotin and idecabtagene vicleucel represent currently available therapies and ongoing trials have demonstrated the efficacy and safety of bispecifics and other BCMA targeting therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BCMA targeting antibody drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies have demonstrated clinical activity in myeloma patients and represent novel therapies in multiple myeloma treatment paradigm.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211073517","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T08:49:35Z","timestamp":1641804575000},"page":"960-968","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[{"name":"MUSC College of Pharmacy, Clinical Pharmacy Specialist \u2013 Malignant Hematology, MUSC Hollings Cancer Center, Charleston, SC, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8479-1430","authenticated-orcid":false,"given":"Abigail","family":"Shockley","sequence":"additional","affiliation":[{"name":"MUSC College of Pharmacy, Medical University of South Carolina, Charleston, SC, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Division of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, SC, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"bibr1-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"bibr2-10781552211073517","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"bibr3-10781552211073517","unstructured":"Myeloma - Cancer Stat Facts. SEER, https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (accessed 1 October 2021)."},{"key":"bibr4-10781552211073517","unstructured":"National Comprehensive Cancer Network. Multiple myeloma (version 4.2021), www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf (accessed 1 October 2021)."},{"key":"bibr5-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"bibr6-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"bibr7-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"bibr8-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"bibr9-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722"},{"key":"bibr10-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805762"},{"key":"bibr11-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"bibr12-10781552211073517","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"bibr13-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7"},{"key":"bibr14-10781552211073517","unstructured":"FDA. Hematology\/Oncology (cancer) approvals & safety notifications, www.fda.gov\/drugs\/resources-information-approved-drugs\/hematologyoncology-cancer-approvals-safety-notifications (accessed 5 October 2021)."},{"key":"bibr15-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"bibr16-10781552211073517","volume-title":"Lexi-drugs online[database on the internet]","year":"2021"},{"key":"bibr17-10781552211073517","volume-title":"Blenrep (belantamab mafodotin) injection [package insert]","year":"2020"},{"key":"bibr18-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32909"},{"key":"bibr19-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0179"},{"key":"bibr20-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"bibr21-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02657"},{"key":"bibr22-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000110"},{"key":"bibr23-10781552211073517","unstructured":"Amgen. A Phase 1b Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and\/or Refractory Multiple Myeloma. Clinical Trial Registration NCT03836053, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03836053 (1 October 2021, accessed 6 October 2021)."},{"key":"bibr24-10781552211073517","unstructured":"Amgen. A Phase 1\/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 Monotherapy, or in Combination With Pomalidomide, With and Without Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (ParadigMM-1B). Clinical Trial Registration NCT03287908, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03287908 (25 August 2021, accessed 6 October 2021)."},{"key":"bibr25-10781552211073517","unstructured":"Amgen. A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1). Clinical Trial Registration NCT04998747, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04998747 (17 September 2021, accessed 6 October 2021)."},{"key":"bibr26-10781552211073517","unstructured":"Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma - The ASCO Post, https:\/\/ascopostcom\/issues\/may-10\u20132021\/bispecific-antibody-platform-early-data-in-relapsed-and-refractory-myeloma\/ (accessed 13 October 2021)."},{"key":"bibr27-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"bibr28-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"bibr29-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"bibr30-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"bibr31-10781552211073517","volume-title":"Lexi-drugs online[database on the internet]","year":"2021"},{"key":"bibr32-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"bibr33-10781552211073517","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8005"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073517","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211073517","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211073517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:57Z","timestamp":1777688757000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211073517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/10781552211073517"],"URL":"https:\/\/doi.org\/10.1177\/10781552211073517","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]}}}